These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

386 related items for PubMed ID: 9211083

  • 1. Troglitazone.
    Spencer CM, Markham A.
    Drugs; 1997 Jul; 54(1):89-101; discussion 102. PubMed ID: 9211083
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Troglitazone: a review of its use in the management of type 2 diabetes mellitus.
    Plosker GL, Faulds D.
    Drugs; 1999 Mar; 57(3):409-38. PubMed ID: 10193691
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.
    Schwartz S, Raskin P, Fonseca V, Graveline JF.
    N Engl J Med; 1998 Mar 26; 338(13):861-6. PubMed ID: 9516220
    [Abstract] [Full Text] [Related]

  • 8. The rise and fall of troglitazone.
    Bailey CJ.
    Diabet Med; 2000 Jun 26; 17(6):414-5. PubMed ID: 10975209
    [No Abstract] [Full Text] [Related]

  • 9. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.
    Kumar S, Boulton AJ, Beck-Nielsen H, Berthezene F, Muggeo M, Persson B, Spinas GA, Donoghue S, Lettis S, Stewart-Long P.
    Diabetologia; 1996 Jun 26; 39(6):701-9. PubMed ID: 8781766
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.
    Sironi AM, Vichi S, Gastaldelli A, Pecori N, Anichini R, Foot E, Seghieri G, Ferrannini E.
    Clin Pharmacol Ther; 1997 Aug 26; 62(2):194-202. PubMed ID: 9284856
    [Abstract] [Full Text] [Related]

  • 13. Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone.
    Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T.
    Diabet Med; 1996 Apr 26; 13(4):365-70. PubMed ID: 9162613
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Clinical results of troglitazone (CS-045)].
    Iwamoto Y.
    Nihon Rinsho; 1997 Nov 26; 55 Suppl():131-6. PubMed ID: 9434456
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Good metabolic and safety profile of troglitazone alone and following alcohol in NIDDM subjects.
    Foot EA, Eastmond R.
    Diabetes Res Clin Pract; 1997 Oct 26; 38(1):41-51. PubMed ID: 9347245
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.